Skip to Main Content

Advertisement

Skip Nav Destination

Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma

December 30, 2021
On location
Amrita Y. Krishnan, MD, shares the promising preliminary results from a phase I/II study of the triplet regimen ixazomib, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X